Metraipolis › archive › dc_a28dbebb9afc
Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study — Europe PMC PMID:42180598
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42180598
- DOI
- 10.1016/j.ahjo.2026.100795
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T13:49:37.716Z
- SHA-256 of the archived text
5c2c2d44ac884cb4854bf9e1befe453c619156cd9edd1aabe800e4ba21fb2855- Stable URL of this page
https://metraipolis.com/documento/dc_a28dbebb9afc
How to cite
Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study — Europe PMC PMID:42180598 — Europe PMC (en), https://europepmc.org/article/MED/42180598 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a28dbebb9afc (Metraipolis archive dc_a28dbebb9afc, sha256 5c2c2d44ac884cb4854bf9e1befe453c619156cd9edd1aabe800e4ba21fb2855)
BibTeX
@misc{dca28dbebb9afc,
title = {Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study — Europe PMC PMID:42180598},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42180598},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a28dbebb9afc; sha256 5c2c2d44ac884cb4854bf9e1befe453c619156cd9edd1aabe800e4ba21fb2855},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42180598. Agents can read the archived copy with the MCP tool read_document.